Recent Posts
- AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions
- AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS
- AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones
- AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
- AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting
Recent Comments
No comments to show.